Lunai Bioworks (LNAI) vs XTL Biopharmaceuticals (XTLB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lunai Bioworks is the larger company by market cap ($4.9 million vs $4.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | LNAI | XTLB |
|---|---|---|
| Share price | $1.09 | $1.98 |
| Market cap | $4.94M | $4.87M |
| 1-day change | -3.54% | -1.98% |
| EPS (TTM) | $-61.36 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.28 | $7.44 |
| 52-week low | $1.09 | $1.98 |
| Distance from 52-week high | -91.79% | -73.39% |
| Average volume | 183.93K | 8.18K |
| Shares outstanding | 4.53M | 2.46M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
LNAI vs XTLB FAQ
Which is bigger, Lunai Bioworks or XTL Biopharmaceuticals?
Lunai Bioworks (LNAI) is larger, with a market capitalization of $4.94M compared with $4.87M for XTL Biopharmaceuticals (XTLB).
Are Lunai Bioworks and XTL Biopharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.